NASDAQ:GTHXG1 Therapeutics Stock Price, Forecast & News

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GTHX shares have increased by 17.1% and is now trading at $16.97. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for G1 Therapeutics.

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for G1 Therapeutics.

G1 Therapeutics Inc (NASDAQ:GTHX) announced its earnings results on Wednesday, May, 6th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.16. View G1 Therapeutics' earnings history.

7 Wall Street analysts have issued 1-year price targets for G1 Therapeutics' shares. Their forecasts range from $23.00 to $82.00. On average, they expect G1 Therapeutics' share price to reach $61.50 in the next twelve months. This suggests a possible upside of 262.4% from the stock's current price. View analysts' price targets for G1 Therapeutics.

Media stories about GTHX stock have been trending negative recently, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. G1 Therapeutics earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutG1 Therapeutics.

G1 Therapeutics saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 2,800,000 shares, a drop of 16.9% from the April 15th total of 3,370,000 shares. Based on an average trading volume of 326,700 shares, the days-to-cover ratio is presently 8.6 days. Approximately 10.2% of the company's shares are sold short. View G1 Therapeutics' Current Options Chain.

Some companies that are related to G1 Therapeutics include Axsome Therapeutics (AXSM), HUTCHISON CHINA/S (HCM), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), Amarin (AMRN), Insmed (INSM), Apellis Pharmaceuticals (APLS), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Turning Point Therapeutics (TPTX), Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH) and IGM Biosciences (IGMS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Rite Aid (RAD), Alibaba Group (BABA), Johnson & Johnson (JNJ), Viking Therapeutics (VKTX), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Sorrento Therapeutics (SRNE), BioCryst Pharmaceuticals (BCRX) and Gilead Sciences (GILD).

(GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

G1 Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.86%), BlackRock Inc. (6.83%), JPMorgan Chase & Co. (4.49%), State Street Corp (3.64%), Geode Capital Management LLC (1.21%) and Deutsche Bank AG (1.15%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends for G1 Therapeutics.

GTHX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Burrage Capital Management LLC, UBS Group AG, Rhenman & Partners Asset Management AB, Alps Advisors Inc., State Street Corp, Virtus ETF Advisers LLC, and Legal & General Group Plc. View insider buying and selling activity for G1 Therapeutics.

GTHX stock was purchased by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Morgan Stanley, 361 Capital LLC, Two Sigma Investments LP, Federated Hermes Inc., Two Sigma Advisers LP, Geode Capital Management LLC, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, James S Hanson, and John Demaree. View insider buying and selling activity for G1 Therapeutics.

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GTHX stock can currently be purchased for approximately $16.97.

G1 Therapeutics has a market capitalization of $640.40 million. The company earns $-122,450,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.

The official website for G1 Therapeutics is www.g1therapeutics.com.

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]